Kymera (KYMR) director granted stock options for 6,068 shares at $99.87

Rhea-AI Filing Summary

Kymera Therapeutics director Sandor Victor received a new stock option grant. On June 24, 2026, he was awarded options covering 6,068 shares of Kymera common stock with an exercise price of $99.87 per share. These options give him the right to buy shares at that price in the future.

The options expire on June 23, 2036. According to the vesting terms, all 6,068 underlying shares will vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual meeting of stockholders. After this grant, Victor holds options for 6,068 shares directly.

Insights

Equity compensation analyst

Routine director option grant with long-dated equity incentive.

This filing shows Sandor Victor, a director of Kymera Therapeutics, receiving 6,068 stock options at an exercise price of $99.87 per share. The transaction is coded as a grant/award, indicating standard equity compensation rather than open-market trading.

The options vest fully on the earlier of the next annual stockholder meeting or June 24, 2027, and expire on June 23, 2036. This structure aligns Victor’s incentives with longer-term share price performance while not involving any immediate cash outlay or share sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sandor Victor

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 6,068 shares Exercise price: $99.87 per share Post-grant option holdings: 6,068 shares +2 more

5 metrics

Option grant size 6,068 shares Stock options granted on June 24, 2026

Exercise price $99.87 per share Stock option (right to buy) strike price

Post-grant option holdings 6,068 shares Total option shares held following transaction

Option expiration June 23, 2036 Expiration date of granted stock options

Full vesting date Earlier of June 24, 2027 or next annual meeting Vesting condition for all 6,068 underlying shares

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "99.8700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying this stock option shall vest in full upon the earlier to occur of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:00 PM Accepted by SEC EDGAR 06/25/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kymera Therapeutics (KYMR) director Sandor Victor report in this Form 4?

Director Sandor Victor reported receiving a stock option grant for 6,068 shares of Kymera common stock. The options are a compensation-related award, not an open-market transaction, giving him the right to buy shares at a fixed exercise price in the future.

How many Kymera Therapeutics (KYMR) shares are covered by Sandor Victor’s new options?

The new stock option grant covers 6,068 shares of Kymera common stock. These options increase Victor’s derivative holdings, giving him potential future ownership if he chooses to exercise them after vesting and before the stated expiration date.

What is the exercise price of Sandor Victor’s Kymera (KYMR) stock options?

The options have an exercise price of $99.87 per share. This means Victor can buy Kymera common stock at $99.87 for each optioned share once vested, regardless of the market price, until the options expire in June 2036.

When do Sandor Victor’s Kymera Therapeutics (KYMR) options vest and become exercisable?

All 6,068 underlying shares vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual meeting of stockholders. After vesting, Victor may choose to exercise the options any time before expiration.

When do Sandor Victor’s new Kymera (KYMR) stock options expire?

The options expire on June 23, 2036. After that date, any unexercised portion of the 6,068-share grant will lapse, and Victor will no longer have the right to purchase Kymera common stock under this specific award.

Did Sandor Victor buy or sell Kymera Therapeutics (KYMR) shares on the market in this filing?

No, this filing reflects a grant of stock options as compensation, not a market trade. The transaction is coded as a grant/award acquisition, meaning it creates the right to buy shares later rather than an immediate purchase or sale.